Evidence map›Paper›PMID 39259360›Full record

ReviewJournal of cancer research and clinical oncology2024

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

O Ortmann, S Schüler-Toprak, K Kast, working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC)

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

O OrtmannDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93055, Regensburg, Germany. olaf.ortmann@klinik.uni-regensburg.de.
S Schüler-ToprakDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93055, Regensburg, Germany.
K KastCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology, Medical Faculty, University Hospital Cologne, Cologne, Germany.
working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions.

methodsEvidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in BRCA1 or BRCA2 (BRCA1/2-pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population.

resultsData on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in BRCA1/2-pV carriers. Premenopausal BRCA1/2-pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency.

conclusionEffect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseBRCA1 ProteinBRCA2 ProteinFemaleGenital Neoplasms, FemaleGermanyHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHormone Replacement TherapyHumansOvarian NeoplasmsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1 and BRCA2Breast cancerFertility treatmentHormone therapyOral contraceptionOvarian cancer

Identifiers

PMID39259360
PMCPMC11390776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.